A headline about a new diabetes medicine being “heart safe” can sound like a simple answer: the drug protects the heart. Clinical trials often mean something more precise.

A new study of oral orforglipron, marketed as Foundayo for its current U.S. weight-management indication, found that it was noninferior to insulin glargine for a defined group of major cardiovascular events in adults with type 2 diabetes and high cardiovascular risk. That is an important result. It means the trial met a preplanned standard showing orforglipron was not meaningfully worse than insulin glargine for that outcome.

It does not prove that the medicine prevents heart attacks, strokes, or cardiovascular death. It does not prove a survival benefit. And it does not mean a person should replace insulin, change a prescription, or assume that one oral medicine is right for everyone with type 2 diabetes.

Understanding that difference helps patients, clinicians, and investors read the research with both interest and accuracy.

What ACHIEVE-4 actually tested

The peer-reviewed ACHIEVE-4 trial was a phase 3, randomized, open-label study that compared once-daily oral orforglipron with once-daily titrated insulin glargine. It enrolled 2,749 adults with type 2 diabetes, a body mass index of at least 25 kg/m², and increased cardiovascular risk. The participants were not a general sample of everyone with type 2 diabetes: 85.9% had established cardiovascular disease and 37.6% had chronic kidney disease.

The study’s primary outcome was MACE-4, short for four-component major adverse cardiovascular events: cardiovascular death, nonfatal heart attack, nonfatal stroke, or hospitalization for unstable angina. The ClinicalTrials.gov record confirms that the study was designed to test time to first MACE-4 event through roughly 104 weeks.

After a median follow-up of two years, the peer-reviewed report recorded a MACE-4 event in 57 of 1,358 orforglipron participants, or 4.2%, and 67 of 1,343 insulin glargine participants, or 5.0%. The hazard ratio was 0.84, with a 95% confidence interval of 0.59 to 1.20.

The trial’s preplanned noninferiority threshold was an upper confidence-interval limit below 1.8. Because the upper limit was 1.20, the trial met that safety standard. Put plainly: in this study, orforglipron was not shown to be unacceptably worse than insulin glargine for MACE-4.

But the confidence interval also crossed 1.0. That means the study did not establish that orforglipron was superior to insulin glargine at preventing major cardiovascular events. A lower point estimate is not enough by itself to prove a lower risk.

Why the lower death count needs careful reading

The study reported 19 deaths among participants receiving orforglipron and 43 among those receiving insulin glargine. It is understandable that this number drew attention. But a finding can be interesting without being conclusive.

In its detailed ACHIEVE-4 release, Lilly notes that the all-cause and cardiovascular-death analyses were not controlled for family-wise type 1 error. In practical terms, the trial was not designed to protect every secondary comparison from a chance-positive result. The peer-reviewed paper therefore supports describing fewer observed deaths, not claiming that the pill saves lives.

That distinction is not a dismissal of the result. It is how clinical science avoids turning a signal into a promise before the evidence is ready. A separate ongoing study, ATTAIN-OUTCOMES, is intended to further evaluate cardiovascular outcomes for orforglipron in adults with established cardiovascular or kidney disease. Until then, the ACHIEVE-4 result should be read as cardiovascular safety against its active comparator—not a proven cardiovascular-benefit claim.

Glucose, weight, and medication tradeoffs still matter

Cardiovascular events were not the only outcomes. Lilly’s study results release reports that at 52 weeks, HbA1c fell by 1.6 percentage points with orforglipron and 1.0 percentage point with insulin glargine. The company also reported an 8.8% mean reduction in body weight with orforglipron, compared with a 1.7% mean increase with insulin glargine. Those results can be meaningful for people and clinicians considering metabolic goals, but they do not make treatment selection automatic.

The tradeoffs were visible too. In the peer-reviewed report, gastrointestinal adverse events occurred in 62.1% of orforglipron participants and 14.2% of insulin glargine participants. Nausea, vomiting, diarrhea, decreased appetite, and constipation were common reasons for considering tolerability and follow-up. Clinically significant or severe hypoglycemia occurred less often with orforglipron than with insulin glargine: 6.8% versus 19.2%.

No one outcome tells the whole story. A treatment decision may also involve current HbA1c, kidney function, cardiovascular history, hypoglycemia risk, medication access, dosing preferences, cost, prior treatment response, side effects, food security, and the person’s goals. An oral option can be valuable for some people, but it is not automatically simpler, more affordable, safer, or more appropriate for every person.

Current approval matters

A study result and a drug label are different things. The FDA approval notice states that Foundayo is approved in the United States for chronic weight management in qualifying adults, alongside a reduced-calorie diet and increased physical activity. It does not identify type 2 diabetes as a current approved indication.

The same FDA notice describes important warnings and precautions, including gastrointestinal effects, pancreatitis, severe gastrointestinal reactions, acute kidney injury due to volume depletion, hypoglycemia in relevant settings, acute gallbladder disease, and a boxed warning about thyroid C-cell tumors. These details do not mean the medicine is inherently harmful. They mean medicine choice, dose escalation, symptom review, and monitoring belong with the clinician who knows a person’s health history and medication plan.

For someone using insulin, this is especially important. Insulin changes can create dangerous high or low glucose levels. A trial comparison is not a personal instruction to stop insulin or switch to a pill.

Whole-person care is not replaced by a pill—or by an injection

At Diabetes Reversal Group, we welcome research that expands evidence-based options for type 2 diabetes. We also believe new medication news should be placed in the full context of health. Food quality and food access, movement, sleep, stress support, relationships, diabetes education, clinical monitoring, and clinician-directed medication all work together.

The American Diabetes Association’s 2026 Standards of Care describe person-centered diabetes care that includes medical nutrition therapy, routine physical activity, adequate sleep, psychosocial care, diabetes self-management education and support, medication-taking support, and shared monitoring. Medication is not a shortcut that makes those supports irrelevant. Whole-person care is not an argument against medication.

For some people, type 2 diabetes remission may be possible with sustained changes and clinical follow-up. Remission is not a cure, and an improved HbA1c during treatment does not by itself establish it. The clinical goal is not to fit every person into one outcome label. It is to reduce risk and support a life that is healthier, sustainable, and realistic.

This article is educational and does not replace individualized medical care. Do not start, stop, reduce, ration, or switch diabetes medication—including insulin—without guidance from the clinician managing your care.